Bifunctional Antibody Retargeting In Vivo-Activated T Lymphocytes: Simplifying Clinical Application

Andrei Chapoval, Heidi Nelson, Claude Thibault, Christopher Penna, Phillip Dean

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

For antitumor x anti-CD3 bifunctional antibody (BFA) therapy to be clinically relevant in solid tumors, activated lymphocytes must be present within tumors. Toward that end, three uniquely different in vivo activation approaches were investigated in a p97 human antigen expressing syngeneic murine melanoma model. β-Glucan (200 μg), staphylocccal enterotoxin B (SEB) (50 μg), and F(ab')2 BFA (10 μg) were tested for their ability to activate lymphocytes, neutralize pulmonary metastases, and treat established tumors. Systemic activation, measured as the ability of splenocytes to lyse tumor cells in vitro in the presence of BFA, was enhanced by the in vivo administration of SEB but not by β-glucan or F(ab')2 BFA. Despite lacking a systemic effect, F(ab')2 BFA increased both direct and BFA-mediated cytotoxicity in fresh tumor infiltrating lymphocytes. β-Glucan did not increase systemic or intratumor T cell activation. However, it significantly enhanced the ability of splenocytes to lyse NK-sensitive YAC-1 cells. When tested in a pulmonary metastases model, all three forms of immune modulation combined with F(ab')2 BFA significantly reduced the number of metastases. BFA were more effective at tumor neutralization when combined with SEB compared with adoptively transferred, in vitro-activated splenocytes. These studies demonstrate that immune modulators when combined with F(ab')2 BFA can provide effective antitumor therapy. Several clinical obstacles may be overcome by the application of these reagents.

Original languageEnglish (US)
Pages (from-to)571-577
Number of pages7
JournalJournal of Hematotherapy and Stem Cell Research
Volume4
Issue number6
DOIs
StatePublished - Jan 1 1995
Externally publishedYes

Fingerprint

Bispecific Antibodies
T-Lymphocytes
Glucans
Enterotoxins
Neoplasms
Neoplasm Metastasis
Lymphocytes
Tumor-Infiltrating Lymphocytes
Lung
Melanoma
Antigens

ASJC Scopus subject areas

  • Immunology
  • Hematology

Cite this

Bifunctional Antibody Retargeting In Vivo-Activated T Lymphocytes : Simplifying Clinical Application. / Chapoval, Andrei; Nelson, Heidi; Thibault, Claude; Penna, Christopher; Dean, Phillip.

In: Journal of Hematotherapy and Stem Cell Research, Vol. 4, No. 6, 01.01.1995, p. 571-577.

Research output: Contribution to journalArticle

Chapoval, Andrei ; Nelson, Heidi ; Thibault, Claude ; Penna, Christopher ; Dean, Phillip. / Bifunctional Antibody Retargeting In Vivo-Activated T Lymphocytes : Simplifying Clinical Application. In: Journal of Hematotherapy and Stem Cell Research. 1995 ; Vol. 4, No. 6. pp. 571-577.
@article{8191f5679fde49ca9ef4cf0800eb9228,
title = "Bifunctional Antibody Retargeting In Vivo-Activated T Lymphocytes: Simplifying Clinical Application",
abstract = "For antitumor x anti-CD3 bifunctional antibody (BFA) therapy to be clinically relevant in solid tumors, activated lymphocytes must be present within tumors. Toward that end, three uniquely different in vivo activation approaches were investigated in a p97 human antigen expressing syngeneic murine melanoma model. β-Glucan (200 μg), staphylocccal enterotoxin B (SEB) (50 μg), and F(ab')2 BFA (10 μg) were tested for their ability to activate lymphocytes, neutralize pulmonary metastases, and treat established tumors. Systemic activation, measured as the ability of splenocytes to lyse tumor cells in vitro in the presence of BFA, was enhanced by the in vivo administration of SEB but not by β-glucan or F(ab')2 BFA. Despite lacking a systemic effect, F(ab')2 BFA increased both direct and BFA-mediated cytotoxicity in fresh tumor infiltrating lymphocytes. β-Glucan did not increase systemic or intratumor T cell activation. However, it significantly enhanced the ability of splenocytes to lyse NK-sensitive YAC-1 cells. When tested in a pulmonary metastases model, all three forms of immune modulation combined with F(ab')2 BFA significantly reduced the number of metastases. BFA were more effective at tumor neutralization when combined with SEB compared with adoptively transferred, in vitro-activated splenocytes. These studies demonstrate that immune modulators when combined with F(ab')2 BFA can provide effective antitumor therapy. Several clinical obstacles may be overcome by the application of these reagents.",
author = "Andrei Chapoval and Heidi Nelson and Claude Thibault and Christopher Penna and Phillip Dean",
year = "1995",
month = "1",
day = "1",
doi = "10.1089/scd.1.1995.4.571",
language = "English (US)",
volume = "4",
pages = "571--577",
journal = "Stem Cells and Development",
issn = "1547-3287",
publisher = "Mary Ann Liebert Inc.",
number = "6",

}

TY - JOUR

T1 - Bifunctional Antibody Retargeting In Vivo-Activated T Lymphocytes

T2 - Simplifying Clinical Application

AU - Chapoval, Andrei

AU - Nelson, Heidi

AU - Thibault, Claude

AU - Penna, Christopher

AU - Dean, Phillip

PY - 1995/1/1

Y1 - 1995/1/1

N2 - For antitumor x anti-CD3 bifunctional antibody (BFA) therapy to be clinically relevant in solid tumors, activated lymphocytes must be present within tumors. Toward that end, three uniquely different in vivo activation approaches were investigated in a p97 human antigen expressing syngeneic murine melanoma model. β-Glucan (200 μg), staphylocccal enterotoxin B (SEB) (50 μg), and F(ab')2 BFA (10 μg) were tested for their ability to activate lymphocytes, neutralize pulmonary metastases, and treat established tumors. Systemic activation, measured as the ability of splenocytes to lyse tumor cells in vitro in the presence of BFA, was enhanced by the in vivo administration of SEB but not by β-glucan or F(ab')2 BFA. Despite lacking a systemic effect, F(ab')2 BFA increased both direct and BFA-mediated cytotoxicity in fresh tumor infiltrating lymphocytes. β-Glucan did not increase systemic or intratumor T cell activation. However, it significantly enhanced the ability of splenocytes to lyse NK-sensitive YAC-1 cells. When tested in a pulmonary metastases model, all three forms of immune modulation combined with F(ab')2 BFA significantly reduced the number of metastases. BFA were more effective at tumor neutralization when combined with SEB compared with adoptively transferred, in vitro-activated splenocytes. These studies demonstrate that immune modulators when combined with F(ab')2 BFA can provide effective antitumor therapy. Several clinical obstacles may be overcome by the application of these reagents.

AB - For antitumor x anti-CD3 bifunctional antibody (BFA) therapy to be clinically relevant in solid tumors, activated lymphocytes must be present within tumors. Toward that end, three uniquely different in vivo activation approaches were investigated in a p97 human antigen expressing syngeneic murine melanoma model. β-Glucan (200 μg), staphylocccal enterotoxin B (SEB) (50 μg), and F(ab')2 BFA (10 μg) were tested for their ability to activate lymphocytes, neutralize pulmonary metastases, and treat established tumors. Systemic activation, measured as the ability of splenocytes to lyse tumor cells in vitro in the presence of BFA, was enhanced by the in vivo administration of SEB but not by β-glucan or F(ab')2 BFA. Despite lacking a systemic effect, F(ab')2 BFA increased both direct and BFA-mediated cytotoxicity in fresh tumor infiltrating lymphocytes. β-Glucan did not increase systemic or intratumor T cell activation. However, it significantly enhanced the ability of splenocytes to lyse NK-sensitive YAC-1 cells. When tested in a pulmonary metastases model, all three forms of immune modulation combined with F(ab')2 BFA significantly reduced the number of metastases. BFA were more effective at tumor neutralization when combined with SEB compared with adoptively transferred, in vitro-activated splenocytes. These studies demonstrate that immune modulators when combined with F(ab')2 BFA can provide effective antitumor therapy. Several clinical obstacles may be overcome by the application of these reagents.

UR - http://www.scopus.com/inward/record.url?scp=0029609436&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029609436&partnerID=8YFLogxK

U2 - 10.1089/scd.1.1995.4.571

DO - 10.1089/scd.1.1995.4.571

M3 - Article

C2 - 8846018

AN - SCOPUS:0029609436

VL - 4

SP - 571

EP - 577

JO - Stem Cells and Development

JF - Stem Cells and Development

SN - 1547-3287

IS - 6

ER -